|
US6783980B2
(en)
*
|
1995-06-15 |
2004-08-31 |
Crucell Holland B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
|
SI0833934T2
(sl)
|
1995-06-15 |
2013-04-30 |
Crucell Holland B.V. |
Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji
|
|
US20030207346A1
(en)
*
|
1997-05-02 |
2003-11-06 |
William R. Arathoon |
Method for making multispecific antibodies having heteromultimeric and common components
|
|
JP4213224B2
(ja)
*
|
1997-05-02 |
2009-01-21 |
ジェネンテック，インコーポレーテッド |
ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
|
|
US7951917B1
(en)
*
|
1997-05-02 |
2011-05-31 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
|
US8236561B2
(en)
*
|
1999-04-15 |
2012-08-07 |
Crucell Holland B.V. |
Efficient production of IgA in recombinant mammalian cells
|
|
US6855544B1
(en)
*
|
1999-04-15 |
2005-02-15 |
Crucell Holland B.V. |
Recombinant protein production in a human cell
|
|
US7297680B2
(en)
*
|
1999-04-15 |
2007-11-20 |
Crucell Holland B.V. |
Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
|
|
US20050164386A1
(en)
*
|
1999-04-15 |
2005-07-28 |
Uytdehaag Alphonsus G. |
Overexpression of enzymes involved in post-translational protein modifications in human cells
|
|
US7521220B2
(en)
*
|
1999-11-26 |
2009-04-21 |
Crucell Holland B.V. |
Production of vaccines
|
|
US7192759B1
(en)
*
|
1999-11-26 |
2007-03-20 |
Crucell Holland B.V. |
Production of vaccines
|
|
US7521053B2
(en)
*
|
2001-10-11 |
2009-04-21 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
|
US7658924B2
(en)
*
|
2001-10-11 |
2010-02-09 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
|
CA2756610C
(en)
*
|
2001-10-29 |
2015-08-25 |
Crucell Holland B.V. |
Methods for producing proteins having n-linked glycans comprising (sialyl-) lewis x or lacdinac structures
|
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
|
NZ537277A
(en)
|
2002-07-18 |
2008-04-30 |
Crucell Holland Bv |
Recombinant production of mixtures of antibodies
|
|
EP2290100B1
(en)
*
|
2002-11-01 |
2014-02-19 |
Iris International, Inc. |
Kits for displacement Sandwich Immuno-PCR
|
|
GB0230201D0
(en)
*
|
2002-12-27 |
2003-02-05 |
Domantis Ltd |
Retargeting
|
|
ES2273202T3
(es)
|
2003-01-07 |
2007-05-01 |
Symphogen A/S |
Procedimiento para producir proteinas policlonales recombinantes.
|
|
WO2004065611A1
(ja)
*
|
2003-01-21 |
2004-08-05 |
Chugai Seiyaku Kabushiki Kaisha |
抗体の軽鎖スクリーニング方法
|
|
EP1626992B1
(en)
*
|
2003-05-23 |
2010-06-02 |
Crucell Holland B.V. |
Production of recombinant igm in per.c6 cells
|
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
|
ES2408582T3
(es)
*
|
2003-05-30 |
2013-06-21 |
Merus B.V. |
Biblioteca de Fab para la preparación de una mezcla de anticuerpos
|
|
EP1508576A1
(en)
*
|
2003-08-20 |
2005-02-23 |
Crucell Holland B.V. |
Efficient production of IgA in recombinant mammalian cells
|
|
DK1737971T3
(da)
|
2004-01-20 |
2017-11-13 |
Merus Nv |
Blandinger af bindingsproteiner
|
|
AU2011218688B2
(en)
*
|
2004-05-27 |
2013-01-10 |
Crucell Holland B.V. |
Binding molecules capable of neutralizing rabies virus and uses thereof
|
|
CN1961002B
(zh)
*
|
2004-05-27 |
2011-05-18 |
克鲁塞尔荷兰公司 |
能中和狂犬病病毒的结合分子及其应用
|
|
US7973134B2
(en)
|
2004-07-07 |
2011-07-05 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
|
|
KR20070038556A
(ko)
|
2004-07-20 |
2007-04-10 |
심포젠 에이/에스 |
항-ｒｈｅｓｕｓ ｄ 재조합 폴리클로날 항체 및 이의 제조방법
|
|
ES2332524T3
(es)
*
|
2004-07-20 |
2010-02-08 |
Symphogen A/S |
Un procedimiento para la caracterizacion de una linea celular policlonal.
|
|
US7935790B2
(en)
|
2004-10-04 |
2011-05-03 |
Cell Singaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
|
|
DE602005023529D1
(de)
*
|
2004-11-03 |
2010-10-21 |
Iris Molecular Diagnostics Inc |
Homogener nachweis von analyten
|
|
CN103091485A
(zh)
*
|
2004-11-03 |
2013-05-08 |
艾瑞斯国际有限公司 |
用于亲和分离的微泡
|
|
US7807789B2
(en)
|
2004-12-21 |
2010-10-05 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
|
|
EP3050963B1
(en)
|
2005-03-31 |
2019-09-18 |
Chugai Seiyaku Kabushiki Kaisha |
Process for production of polypeptide by regulation of assembly
|
|
CA2603264C
(en)
*
|
2005-04-08 |
2017-03-21 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody substituting for function of blood coagulation factor viii
|
|
CA2606081C
(en)
|
2005-04-26 |
2013-09-17 |
Markus M. Heiss |
Combination of the application of antibodies for immunostimulation together with glucocorticoids
|
|
EP1934867A2
(en)
|
2005-08-31 |
2008-06-25 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in leukemia signaling pathways
|
|
US20070111237A1
(en)
*
|
2005-09-14 |
2007-05-17 |
Maurizio Zanetti |
Process for identifying antigenized antibodies using ribosome cell free expression system
|
|
AU2012201010B2
(en)
*
|
2005-10-21 |
2015-01-22 |
Genzyme Corporation |
Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use
|
|
KR20080068089A
(ko)
*
|
2005-10-21 |
2008-07-22 |
지티씨바이오쎄라퓨틱스,인크. |
항체 의존성 세포 독성 활성이 증강된 항체, 그 생산 및사용 방법
|
|
DE102005054628A1
(de)
*
|
2005-11-16 |
2007-05-24 |
Cevec Pharmaceuticals Gmbh |
Verfahren zur Herstellung von permanenten humanen Zelllinien
|
|
EP2314619A1
(en)
|
2005-12-05 |
2011-04-27 |
Symphogen A/S |
Anti-orthopoxvirus recombinant polyclonal antibody
|
|
WO2009051846A2
(en)
|
2007-10-18 |
2009-04-23 |
Cell Signaling Technology, Inc. |
Translocation and mutant ros kinase in human non-small cell lung carcinoma
|
|
US20120208824A1
(en)
|
2006-01-20 |
2012-08-16 |
Cell Signaling Technology, Inc. |
ROS Kinase in Lung Cancer
|
|
AU2007215739B2
(en)
*
|
2006-02-17 |
2014-01-16 |
Atsuo Sekiyama |
Biological load indicator and method of measuring biological load
|
|
PL3167888T3
(pl)
|
2006-03-15 |
2024-08-26 |
Alexion Pharmaceuticals, Inc. |
Leczenie pacjentów z napadową nocną hemoglobinurią za pomocą inhibitora dopełniacza
|
|
ES2892925T3
(es)
|
2006-03-31 |
2022-02-07 |
Chugai Pharmaceutical Co Ltd |
Métodos para controlar la farmacocinética en sangre de anticuerpos
|
|
US9670269B2
(en)
|
2006-03-31 |
2017-06-06 |
Chugai Seiyaku Kabushiki Kaisha |
Methods of modifying antibodies for purification of bispecific antibodies
|
|
US7939636B2
(en)
|
2006-08-11 |
2011-05-10 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in c-Src signaling pathways
|
|
ATE536374T1
(de)
|
2006-09-01 |
2011-12-15 |
Therapeutic Human Polyclonals Inc |
Erhöhte expression von humanem oder humanisiertem immunglobulin bei nicht-humanen transgenen tieren
|
|
CA2662480C
(en)
|
2006-09-05 |
2016-11-08 |
Alexion Pharmaceuticals, Inc. |
Methods and compositions for the treatment of antibody mediated neuropathies
|
|
CN101557799B
(zh)
|
2006-12-05 |
2012-08-22 |
克鲁塞尔荷兰公司 |
液体抗狂犬病抗体制剂
|
|
CN101675075B
(zh)
|
2007-03-01 |
2014-06-18 |
西福根有限公司 |
重组抗表皮生长因子受体抗体组合物
|
|
EP1972639A3
(en)
|
2007-03-07 |
2008-12-03 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
|
EP1975184A3
(en)
|
2007-03-26 |
2008-11-26 |
Cell Signaling Technology, Inc. |
Serine or threonine phosphorylation sites
|
|
NL1033696C2
(nl)
*
|
2007-04-16 |
2008-10-20 |
Friesland Brands Bv |
Aan melk ontleende antigeen-specifieke antilichamen, werkwijzen voor het bereiden en gebruik ervan.
|
|
EP1983003A3
(en)
|
2007-04-19 |
2009-03-11 |
Peter Hornbeck |
Tyrosine phosphorylation sites and antibodies specific for them
|
|
EP1983002A3
(en)
|
2007-04-19 |
2009-03-11 |
Peter Hornbeck |
Tyrosine phosphorylation sites and antibodies specific for them
|
|
US7977462B2
(en)
|
2007-04-19 |
2011-07-12 |
Cell Signaling Technology, Inc. |
Tyrosine phosphorylation sites
|
|
US20090053831A1
(en)
|
2007-05-01 |
2009-02-26 |
Cell Signaling Technology, Inc. |
Tyrosine phosphorylation sites
|
|
HRP20100640T1
(hr)
*
|
2007-05-25 |
2010-12-31 |
Symphogen A/S |
Postupak proizvodnje rekombinantnog poliklonskog proteina
|
|
WO2009002380A2
(en)
*
|
2007-06-26 |
2008-12-31 |
The Trustees Of The University Of Pennsylvania |
Isolation of anti-desmoglein 1 antibodies by phage display of pemphigus foliaceus autoantibodies
|
|
CN101874042B9
(zh)
|
2007-09-26 |
2019-01-01 |
中外制药株式会社 |
利用cdr的氨基酸取代来改变抗体等电点的方法
|
|
EP2062920A3
(en)
|
2007-11-21 |
2009-06-17 |
Peter Hornbeck |
Protein phosphorylation by basophilic serine/threonine kinases in insulin signalling pathways
|
|
JO2913B1
(en)
|
2008-02-20 |
2015-09-15 |
امجين إنك, |
Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
|
|
CN103884840A
(zh)
*
|
2008-02-21 |
2014-06-25 |
艾瑞斯国际有限公司 |
早期确定前列腺癌治疗后复发的方法
|
|
EP2098536A1
(en)
|
2008-03-05 |
2009-09-09 |
4-Antibody AG |
Isolation and identification of antigen- or ligand-specific binding proteins
|
|
EP2274437B1
(en)
|
2008-04-10 |
2015-12-23 |
Cell Signaling Technology, Inc. |
Compositions and methods for detecting egfr mutations in cancer
|
|
RU2010147652A
(ru)
*
|
2008-04-23 |
2012-05-27 |
Симфоген А/С (Dk) |
Способы производства поликлонального белка
|
|
BRPI0910482A2
(pt)
|
2008-04-29 |
2019-09-24 |
Abbott Lab |
imunoglobinas de domínio variável duplo e usos das mesmas
|
|
PE20100092A1
(es)
|
2008-06-03 |
2010-03-12 |
Abbott Lab |
Inmunoglobulina con dominio variable dual y usos de la misma
|
|
PL3456190T3
(pl)
*
|
2008-06-27 |
2022-06-06 |
Merus N.V. |
Wytwarzające przeciwciała transgeniczne zwierzę z gatunku myszy
|
|
US8148088B2
(en)
|
2008-07-18 |
2012-04-03 |
Abgent |
Regulation of autophagy pathway phosphorylation and uses thereof
|
|
US8663640B2
(en)
|
2008-08-29 |
2014-03-04 |
Symphogen A/S |
Methods using recombinant anti-epidermal growth factor receptor antibody compositions
|
|
EP2159291A1
(en)
|
2008-09-01 |
2010-03-03 |
Agendia B.V. |
Means and method for determining tumor cell percentage in a sample
|
|
US20120020952A1
(en)
*
|
2009-01-26 |
2012-01-26 |
Genmab A/S |
Methods for producing mixtures of antibodies
|
|
WO2010089387A1
(en)
|
2009-02-09 |
2010-08-12 |
Morphosys Ag |
Production of oligoclonal mixtures of immunoglobulins in single cells
|
|
AU2010213578B2
(en)
|
2009-02-12 |
2015-01-29 |
Cell Signaling Technology, Inc. |
Mutant ROS expression in human cancer
|
|
EP2403531A4
(en)
|
2009-03-05 |
2013-02-27 |
Abbott Lab |
IL-17 BINDING PROTEINS
|
|
JP2012525149A
(ja)
*
|
2009-04-27 |
2012-10-22 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
ヘテロ多量体分子を作製するための方法
|
|
JP5816170B2
(ja)
*
|
2009-06-26 |
2015-11-18 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
|
|
BR112012000536A2
(pt)
|
2009-07-08 |
2020-08-11 |
Kymab Limited |
métodos para produção de anticorpo ou cadeia leve ou pesada de anticorpo específico para um antígeno desejado, para produção de anticorpo ou cadeia de anticorpo e seu uso, composição farmacêutica e derivado de anticorpo quimérico
|
|
WO2011025964A2
(en)
|
2009-08-29 |
2011-03-03 |
Abbott Laboratories |
Therapeutic dll4 binding proteins
|
|
EP2507381A4
(en)
*
|
2009-12-04 |
2016-07-20 |
Hoffmann La Roche |
MULTISPECIFIC ANTIBODIES, ANTIBODY ANALOGS, COMPOSITIONS AND METHODS
|
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
|
US20120021409A1
(en)
*
|
2010-02-08 |
2012-01-26 |
Regeneron Pharmaceuticals, Inc. |
Common Light Chain Mouse
|
|
SI2501817T2
(sl)
*
|
2010-02-08 |
2021-09-30 |
Regeneron Pharmaceuticals, Inc. |
Miš z navadno lahko verigo
|
|
BR112012021941A2
(pt)
|
2010-03-02 |
2022-02-01 |
Abbvie Inc |
Proteínas terapêuticas de ligação a dll4
|
|
CN102946906B
(zh)
|
2010-04-23 |
2015-07-15 |
弗·哈夫曼-拉罗切有限公司 |
生产异源多聚体蛋白质
|
|
KR101539684B1
(ko)
|
2010-05-14 |
2015-07-27 |
애브비 인코포레이티드 |
Ｉｌ－１ 결합 단백질
|
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
SG10201912639SA
(en)
|
2010-08-02 |
2020-02-27 |
Regeneron Pharma |
Mice that make binding proteins comprising vl domains
|
|
US8735546B2
(en)
|
2010-08-03 |
2014-05-27 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
US20120101108A1
(en)
|
2010-08-06 |
2012-04-26 |
Cell Signaling Technology, Inc. |
Anaplastic Lymphoma Kinase In Kidney Cancer
|
|
PL2606064T3
(pl)
*
|
2010-08-16 |
2015-07-31 |
Novimmune Sa |
Sposoby wytwarzania wieloswoistych i wielowartościowych przeciwciał
|
|
PE20140229A1
(es)
|
2010-08-26 |
2014-03-27 |
Abbvie Inc |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
CA2810016A1
(en)
|
2010-09-03 |
2012-03-08 |
Stem Centrx, Inc. |
Novel modulators and methods of use
|
|
PH12016502073B1
(en)
|
2010-11-17 |
2024-04-05 |
Chugai Pharmaceutical Co Ltd |
Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
|
|
CN103517921B
(zh)
|
2010-12-21 |
2017-07-18 |
Abbvie 公司 |
IL‑1‑α和‑β双特异性双重可变结构域免疫球蛋白及其用途
|
|
WO2012094321A1
(en)
|
2011-01-03 |
2012-07-12 |
Avm Biotechnology, Llc |
Personalized production of biologics and method for reprogramming somatic cells
|
|
RU2722373C2
(ru)
|
2011-02-25 |
2020-05-29 |
Редженерон Фармасьютикалс, Инк. |
Мыши adam6
|
|
WO2012122512A1
(en)
|
2011-03-10 |
2012-09-13 |
Hco Antibody, Inc. |
Recombinant production of mixtures of single chain antibodies
|
|
US9244074B2
(en)
|
2011-06-07 |
2016-01-26 |
University Of Hawaii |
Biomarker of asbestos exposure and mesothelioma
|
|
WO2012170742A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Treatment and prevention of cancer with hmgb1 antagonists
|
|
UA117901C2
(uk)
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
|
|
RS59728B1
(sr)
*
|
2011-08-05 |
2020-02-28 |
Regeneron Pharma |
Humanizovani miševi univerzalnog lakog lanca
|
|
BR112014006394A2
(pt)
|
2011-09-19 |
2017-03-28 |
Kymab Ltd |
manipulação de diversidade genética de imunoglobulina e terapêuticos multi-anticorpos
|
|
LT3485903T
(lt)
|
2011-09-23 |
2023-02-27 |
Mereo Biopharma 5, Inc. |
Vegf/ dll4 surišantys agentai ir jų panaudojimas
|
|
CA2791109C
(en)
|
2011-09-26 |
2021-02-16 |
Merus B.V. |
Generation of binding molecules
|
|
CN107266577B
(zh)
|
2011-10-11 |
2022-09-13 |
弗·哈夫曼-拉罗切有限公司 |
双特异性抗体的改进的组装
|
|
KR20160098514A
(ko)
|
2011-10-17 |
2016-08-18 |
리제너론 파아마슈티컬스, 인크. |
제한된 면역글로불린 중쇄 마우스
|
|
AU2012328917B2
(en)
|
2011-10-24 |
2017-05-25 |
Abbvie Inc. |
Bispecific immunobinders directed against TNF and IL-17
|
|
JP2014533659A
(ja)
|
2011-10-24 |
2014-12-15 |
アッヴィ・インコーポレイテッド |
スクレロスチンに対するイムノバインダー
|
|
AU2012332588B2
(en)
|
2011-11-01 |
2017-09-07 |
Bionomics, Inc. |
Methods of blocking cancer stem cell growth
|
|
EP2773664A1
(en)
|
2011-11-01 |
2014-09-10 |
Bionomics, Inc. |
Anti-gpr49 antibodies
|
|
US9221907B2
(en)
|
2011-11-01 |
2015-12-29 |
Bionomics Inc. |
Anti-GPR49 monoclonal antibodies
|
|
WO2013067054A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Antibodies and methods of treating cancer
|
|
RU2664181C2
(ru)
|
2011-12-20 |
2018-08-15 |
Регенерон Фармасьютикалз, Инк. |
Мыши с гуманизированной легкой цепью
|
|
US9175072B2
(en)
|
2011-12-22 |
2015-11-03 |
Elwha Llc |
Compositions and methods including recombinant B lymphocyte cell line including an exogenously incorporated nucleic acid expressing an exogenous membrane immunoglobulin reactive to a first antigen and including an endogenous gene expressing an endogenous secreted immunoglobulin reactive to a second antigen
|
|
US8962315B2
(en)
*
|
2011-12-22 |
2015-02-24 |
Elwha Llc |
Compositions and methods including recombinant B lymphocyte cell line including at least one endogenous gene expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and including at least one exogenously incorporated nucleic acid expressing at least one exogenous secreted immunoglobulin reactive to a second antigen
|
|
US10233424B2
(en)
|
2011-12-22 |
2019-03-19 |
Elwha Llc |
Compositions and methods including cytotoxic B lymphocyte cell line expressing exogenous membrane immunoglobulin different from secreted immunoglobulin
|
|
US10745468B2
(en)
|
2011-12-22 |
2020-08-18 |
Kota Biotherapeutics, Llc |
Compositions and methods for modified B cells expressing reassigned biological agents
|
|
US20130171059A1
(en)
|
2011-12-30 |
2013-07-04 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
AR089529A1
(es)
|
2011-12-30 |
2014-08-27 |
Abbvie Inc |
Proteinas de union especificas duales dirigidas contra il-13 y/o il-17
|
|
US9550830B2
(en)
|
2012-02-15 |
2017-01-24 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
|
|
IN2014DN08163A
(https=)
*
|
2012-03-06 |
2015-05-01 |
Regeneron Pharma |
|
|
US20140013456A1
(en)
|
2012-03-16 |
2014-01-09 |
Regeneron Pharmaceuticals, Inc. |
Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
|
|
MX2014011047A
(es)
|
2012-03-16 |
2015-04-08 |
Regeneron Pharma |
Ratones que producen proteinas de union a un antigeno con caracteristicas de union dependientes del ph.
|
|
SG10201700360VA
(en)
|
2012-03-16 |
2017-03-30 |
Regeneron Pharma |
Non-human animals expressing ph-sensitive immunoglobulin sequences
|
|
KR102228296B1
(ko)
|
2012-03-16 |
2021-03-17 |
리제너론 파마슈티칼스 인코포레이티드 |
히스티딘 공학처리된 경쇄 항체 및 그것을 생성하기 위한 유전자 변형된 비-사람 동물
|
|
US10251377B2
(en)
|
2012-03-28 |
2019-04-09 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
|
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
|
DK2838998T3
(en)
|
2012-04-18 |
2018-01-15 |
Cell Signaling Technology Inc |
EGFR AND ROS1 IN CANCER
|
|
SI2838917T1
(sl)
|
2012-04-20 |
2019-11-29 |
Merus Nv |
Postopki in sredstva za produkcijo heterodimernih IG-podobnih molekul
|
|
DK2847231T3
(da)
*
|
2012-05-10 |
2019-10-14 |
Bioatla Llc |
Multispecifikke monoklonale antistoffer
|
|
PT3597037T
(pt)
|
2012-06-12 |
2021-06-01 |
Regeneron Pharma |
Animais não humanos humanizados com lócus de cadeia pesada de imunoglobulina restrito
|
|
BR112015000167B1
(pt)
|
2012-07-06 |
2021-11-23 |
Genmab B.V. |
Proteína dimérica, proteína, composição, kit de partes e seus usos, bem como método para aumentar a oligomerização em solução de uma proteína dimérica compreendendo um primeiro e segundo polipeptídeo, cada um compreendendo pelo menos as regiões ch2 e ch3 de uma cadeia pesada de igg1 humana e proteína dimérica variante
|
|
EP3632462A1
(en)
|
2012-07-06 |
2020-04-08 |
Genmab B.V. |
Dimeric protein with triple mutations
|
|
UY34905A
(es)
|
2012-07-12 |
2014-01-31 |
Abbvie Inc |
Proteínas de unión a il-1
|
|
CN102851338A
(zh)
|
2012-07-25 |
2013-01-02 |
苏州康宁杰瑞生物科技有限公司 |
利用电荷排斥作用制备同二聚体蛋白混合物的方法
|
|
ES2456823B1
(es)
*
|
2012-09-21 |
2015-01-27 |
Consejo Superior De Investigaciones Científicas (Csic) |
Método de producción de repertorios complejos de moléculas recombinantes
|
|
EP3470431A1
(en)
*
|
2012-09-27 |
2019-04-17 |
Merus N.V. |
Bispecific igg antibodies as t cell engagers
|
|
KR20180008921A
(ko)
|
2012-11-01 |
2018-01-24 |
애브비 인코포레이티드 |
항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도
|
|
AU2013339038B2
(en)
*
|
2012-11-05 |
2017-12-21 |
Zenyaku Kogyo Kabushikikaisha |
Antibody and antibody composition production method
|
|
EP2928919A2
(en)
|
2012-12-04 |
2015-10-14 |
AbbVie Inc. |
Blood-brain barrier (bbb) penetrating dual specific binding proteins
|
|
EP2938634A2
(en)
|
2012-12-28 |
2015-11-04 |
AbbVie Inc. |
Dual specific binding proteins having a receptor sequence
|
|
US9856319B2
(en)
|
2012-12-28 |
2018-01-02 |
Abbvie Inc. |
Monovalent binding proteins
|
|
KR20200024345A
(ko)
|
2013-01-10 |
2020-03-06 |
젠맵 비. 브이 |
인간 IgG1 Fc 영역 변이체 및 그의 용도
|
|
US9222142B2
(en)
*
|
2013-01-15 |
2015-12-29 |
The Regents Of The University Of California |
Adenoviruses and their use
|
|
EP2840892B1
(en)
|
2013-02-20 |
2018-04-18 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals with modified immunoglobulin heavy chain sequences
|
|
CN105189545A
(zh)
*
|
2013-03-13 |
2015-12-23 |
瑞泽恩制药公司 |
常见轻链小鼠
|
|
CN105324396A
(zh)
|
2013-03-15 |
2016-02-10 |
艾伯维公司 |
针对IL-1β和/或IL-17的双重特异性结合蛋白
|
|
TW201446800A
(zh)
|
2013-03-15 |
2014-12-16 |
Abbvie Inc |
針對ＴＮＦα之雙特異性結合蛋白
|
|
US9788534B2
(en)
|
2013-03-18 |
2017-10-17 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
US11707056B2
(en)
|
2013-05-02 |
2023-07-25 |
Kymab Limited |
Animals, repertoires and methods
|
|
US9783593B2
(en)
|
2013-05-02 |
2017-10-10 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
|
MX373245B
(es)
|
2013-07-05 |
2020-05-11 |
Genmab As |
Anticuerpos cd3 humanizados o quiméricos.
|
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
|
JP6534615B2
(ja)
|
2013-09-27 |
2019-06-26 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
|
DE112014004537T5
(de)
|
2013-10-01 |
2016-07-21 |
Kymab Limited |
Tiermodelle und therapeutische Moleküle
|
|
MX2016004420A
(es)
|
2013-10-06 |
2017-03-31 |
Abbvie Inc |
Proteinas de union especificas duales dirigidas contra los receptores de células inmunes y autoantígenos de señalización de tlr.
|
|
WO2015084883A2
(en)
|
2013-12-02 |
2015-06-11 |
Abbvie, Inc. |
Compositions and methods for treating osteoarthritis
|
|
JP2017512208A
(ja)
*
|
2014-02-10 |
2017-05-18 |
アイジーエム バイオサイエンス， インコーポレイテッド |
ＩｇＡ多重特異性結合分子
|
|
IL301147A
(en)
|
2014-02-28 |
2023-05-01 |
Merus Nv |
An antibody that binds to ErbB-2 and ErbB-3
|
|
EP3786186A1
(en)
|
2014-02-28 |
2021-03-03 |
Merus N.V. |
Antibodies that bind egfr and erbb3
|
|
KR102276752B1
(ko)
|
2014-03-21 |
2021-07-13 |
리제너론 파마슈티칼스 인코포레이티드 |
단일 도메인 결합 단백질을 생산하는 비-인간 동물
|
|
WO2015143406A2
(en)
|
2014-03-21 |
2015-09-24 |
Regeneron Pharmaceuticals, Inc. |
Vl antigen binding proteins exhibiting distinct binding characteristics
|
|
EP3126384B1
(en)
|
2014-04-01 |
2020-12-02 |
Adimab, LLC |
Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use
|
|
IL292311A
(en)
|
2014-04-03 |
2022-06-01 |
Igm Biosciences Inc |
J-chain qualified
|
|
CA2944649C
(en)
|
2014-04-04 |
2022-06-21 |
Bionomics, Inc. |
Humanized antibodies that bind lgr5
|
|
CA2943707A1
(en)
|
2014-05-06 |
2015-11-12 |
Genentech, Inc. |
Production of heteromultimeric proteins using mammalian cells
|
|
PE20170261A1
(es)
|
2014-05-13 |
2017-04-12 |
Univ Pennsylvania |
Composiciones que comprenden virus adenoasociado (aav) que expresa constructos de anticuerpos duales y sus usos
|
|
MX370807B
(es)
|
2014-07-11 |
2020-01-08 |
Genmab As |
Anticuerpos que se unen a axl.
|
|
AR101262A1
(es)
|
2014-07-26 |
2016-12-07 |
Regeneron Pharma |
Plataforma de purificación para anticuerpos biespecíficos
|
|
TWI701435B
(zh)
|
2014-09-26 |
2020-08-11 |
日商中外製藥股份有限公司 |
測定ｆｖｉｉｉ的反應性之方法
|
|
TWI700300B
(zh)
|
2014-09-26 |
2020-08-01 |
日商中外製藥股份有限公司 |
中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
|
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
|
JP6863888B2
(ja)
|
2014-10-01 |
2021-04-21 |
メディミューン，エルエルシー |
ポリペプチドをコンジュゲートさせる方法
|
|
WO2016094881A2
(en)
|
2014-12-11 |
2016-06-16 |
Abbvie Inc. |
Lrp-8 binding proteins
|
|
CN110655582B
(zh)
|
2015-01-08 |
2022-12-16 |
江苏康宁杰瑞生物制药有限公司 |
具有共同轻链的双特异性抗体或抗体混合物
|
|
CN107660214B
(zh)
|
2015-01-08 |
2022-02-08 |
根马布股份公司 |
针对cd3和cd20的双特异性抗体
|
|
PT3247728T
(pt)
|
2015-01-20 |
2020-07-16 |
Igm Biosciences Inc |
Moléculas de ligação do recetor da superfamília do fator de necrose tumoral (fnt) e utilização das mesmas
|
|
KR102357312B1
(ko)
*
|
2015-03-04 |
2022-02-03 |
아이쥐엠 바이오사이언스 인코포레이티드 |
Ｃｄ20 결합 분자 및 그의 용도
|
|
EP3271403A1
(en)
|
2015-03-19 |
2018-01-24 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that select for light chain variable regions that bind antigen
|
|
JP7082484B2
(ja)
|
2015-04-01 |
2022-06-08 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
|
|
SI3115376T1
(sl)
|
2015-07-10 |
2018-12-31 |
Merus N.V. |
Humana protitelesa, ki vežejo CD3
|
|
CN108368171A
(zh)
|
2015-07-10 |
2018-08-03 |
根马布股份公司 |
用于癌症治疗的axl特异性抗体-药物缀合物
|
|
CN108368172B
(zh)
|
2015-07-15 |
2022-06-14 |
根马布股份公司 |
人源化或嵌合cd3抗体
|
|
RU2018109739A
(ru)
*
|
2015-08-27 |
2019-09-20 |
Кристал Байосайнс Инк. |
Трансгенное животное для получения антител, имеющих общую легкую цепь
|
|
EP3356401B1
(en)
|
2015-09-30 |
2020-06-24 |
IGM Biosciences, Inc. |
Binding molecules with modified j-chain
|
|
EP3824903A1
(en)
|
2015-09-30 |
2021-05-26 |
IGM Biosciences Inc. |
Binding molecules with modified j-chain
|
|
CA3002957A1
(en)
|
2015-10-23 |
2017-04-27 |
Koninklijke Nederlandse Akademie Van Wetenschappen |
Binding molecules that inhibit cancer growth
|
|
US20200270363A1
(en)
|
2015-12-25 |
2020-08-27 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody having enhanced activity, and method for modifying same
|
|
CN108368166B
(zh)
|
2015-12-28 |
2023-03-28 |
中外制药株式会社 |
提高含fc区多肽纯化效率的方法
|
|
CN108495653A
(zh)
|
2016-01-27 |
2018-09-04 |
免疫医疗有限责任公司 |
用于制备具有定义的糖基化模式抗体的方法
|
|
WO2017165464A1
(en)
|
2016-03-21 |
2017-09-28 |
Elstar Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
|
EP3432925A4
(en)
|
2016-03-22 |
2019-11-06 |
Bionomics Limited |
ADMINISTRATION OF A MONOCLONAL ANTI-LGR5 ANTIBODY
|
|
MA44780A
(fr)
|
2016-04-28 |
2019-03-06 |
Chugai Pharmaceutical Co Ltd |
Préparation contenant un anticorps
|
|
AU2017269115B2
(en)
|
2016-05-26 |
2024-06-20 |
Qilu Puget Sound Biotherapeutics Corporation |
Mixtures of antibodies
|
|
SG11201811431VA
(en)
|
2016-07-14 |
2019-01-30 |
Genmab As |
Multispecific antibodies against cd40 and cd137
|
|
KR102591955B1
(ko)
|
2016-07-29 |
2023-10-19 |
추가이 세이야쿠 가부시키가이샤 |
증강된 fviii 보인자 기능 대체 활성을 갖는 이중특이성 항체
|
|
RU2766233C2
(ru)
|
2016-09-06 |
2022-02-10 |
Чугаи Сейяку Кабусики Кайся |
Способы применения биспецифического антитела, которое распознает фактор свертывания ix и/или активированный фактор свертывания ix и фактор свертывания x и/или активированный фактор свертывания x
|
|
BR112019005895A2
(pt)
|
2016-09-23 |
2019-06-11 |
Merus N.V. |
moléculas de ligação que modulam uma atividade biológica expressa por uma célula
|
|
SG11201903693QA
(en)
|
2016-11-01 |
2019-05-30 |
Genmab Bv |
Polypeptide variants and uses thereof
|
|
WO2018098553A1
(en)
*
|
2016-12-01 |
2018-06-07 |
Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence |
Production of ricin antibodies in plant
|
|
SG11201905259SA
(en)
*
|
2017-02-02 |
2019-08-27 |
Merck Patent Gmbh |
Preferred pairing of antibody domains
|
|
KR20250140128A
(ko)
|
2017-02-10 |
2025-09-24 |
젠맵 비. 브이 |
폴리펩티드 변이체 및 그의 용도
|
|
WO2018151820A1
(en)
|
2017-02-16 |
2018-08-23 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
|
BR112019018533A2
(pt)
|
2017-03-09 |
2020-04-14 |
Genmab A/S |
anticorpo, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição farmacêutica, método para tratar uma doença, e, uso de um anticorpo
|
|
AU2018246873B2
(en)
|
2017-03-31 |
2021-05-06 |
Merus B.V. |
ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment f cells that have an NRG1 fusion gene
|
|
CN110461358A
(zh)
|
2017-03-31 |
2019-11-15 |
公立大学法人奈良县立医科大学 |
可用于预防和/或治疗凝血因子ⅸ异常、包含代替凝血因子ⅷ的功能的多特异性抗原结合分子的药物组合物
|
|
AU2018246872C1
(en)
|
2017-03-31 |
2023-05-18 |
Merus B.V. |
ErbB-2 targeting agent and a bispecific antibody with antigen-binding sites that bind an epitope on an extracellular part of erb-2 and erbB-3, for treatment of an individual with an erbB-2, erbB-2/erbB-3 positive tumour
|
|
EP3601354A1
(en)
|
2017-03-31 |
2020-02-05 |
Genmab Holding B.V. |
Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
|
|
WO2018212656A1
(en)
|
2017-05-17 |
2018-11-22 |
Merus N.V. |
Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
|
|
AR111963A1
(es)
|
2017-05-26 |
2019-09-04 |
Univ California |
Método y moléculas
|
|
JP2020522254A
(ja)
|
2017-05-31 |
2020-07-30 |
エルスター セラピューティクス， インコーポレイテッド |
骨髄増殖性白血病（ｍｐｌ）タンパク質に結合する多特異性分子およびその使用
|
|
UY37758A
(es)
|
2017-06-12 |
2019-01-31 |
Novartis Ag |
Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
|
|
EP3649155A1
(en)
|
2017-07-06 |
2020-05-13 |
Merus N.V. |
Bispecific anti pd1-anti tim3 antibodies
|
|
EA202090003A1
(ru)
|
2017-07-06 |
2020-06-18 |
Мерус Н.В. |
Связывающие молекулы, модулирующие биологическую активность, которую проявляет клетка
|
|
EA202090005A1
(ru)
|
2017-07-06 |
2020-06-18 |
Мерус Н.В. |
Антитела, модулирующие биологическую активность, проявляемую клеткой
|
|
GB201710984D0
(en)
*
|
2017-07-07 |
2017-08-23 |
Kymab Ltd |
Cells, vertebrates, populations & methods
|
|
SG11202000198QA
(en)
|
2017-08-04 |
2020-02-27 |
Genmab As |
Binding agents binding to pd-l1 and cd137 and use thereof
|
|
CN118580366A
(zh)
|
2017-08-09 |
2024-09-03 |
美勒斯公司 |
结合EGFR和cMET的抗体
|
|
AR113142A1
(es)
|
2017-09-29 |
2020-01-29 |
Chugai Pharmaceutical Co Ltd |
Moléculas de unión al antígeno multiespecíficas que tienen actividad de sustitución de la función de cofactor del factor viii de coagulación de sangre (fviii), y formulaciones farmacéuticas que contienen dicha molécula como ingrediente activo
|
|
AU2018361430B2
(en)
|
2017-11-01 |
2025-08-14 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody variant and isoform with lowered biological activity
|
|
CN111699003B
(zh)
*
|
2017-12-19 |
2024-05-03 |
瑟罗泽恩奥普瑞汀公司 |
抗lrp5/6抗体和使用方法
|
|
EP3732201A4
(en)
|
2017-12-19 |
2022-04-20 |
Surrozen Operating, Inc. |
WNT SURROGATES AND THEIR USES
|
|
EP3737692A4
(en)
|
2018-01-09 |
2021-09-29 |
Elstar Therapeutics, Inc. |
CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
|
|
EP3743440A1
(en)
|
2018-01-24 |
2020-12-02 |
Genmab B.V. |
Polypeptide variants and uses thereof
|
|
TWI849895B
(zh)
|
2018-02-09 |
2024-07-21 |
日商小野藥品工業股份有限公司 |
雙特異性抗體
|
|
SG11202008399QA
(en)
|
2018-03-12 |
2020-09-29 |
Genmab As |
Antibodies
|
|
US12152073B2
(en)
|
2018-03-14 |
2024-11-26 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
WO2019178364A2
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
EP3768707A4
(en)
*
|
2018-03-19 |
2022-01-26 |
The Invention Science Fund II, LLC |
COMPOSITIONS AND METHODS FOR MODIFIED B CELLS EXPRESSING REALIZED BIOLOGICAL AGENTS
|
|
MX2020010267A
(es)
|
2018-03-30 |
2020-11-06 |
Merus Nv |
Anticuerpo multivalente.
|
|
BR112020022179A2
(pt)
|
2018-05-03 |
2021-02-02 |
Genmab B.V. |
primeiro anticorpo, anticorpo, composição, métodos para tratar um indivíduo tendo uma doença, para esgotar uma população de célula e para induzir a proliferação em uma população de célula, e, kit.
|
|
WO2019243636A1
(en)
|
2018-06-22 |
2019-12-26 |
Genmab Holding B.V. |
Anti-cd37 antibodies and anti-cd20 antibodies, compositions and methods of use thereof
|
|
CN112513074A
(zh)
|
2018-06-22 |
2021-03-16 |
健玛保 |
生产两种或更多种不同抗体的受控混合物的方法
|
|
EP3818083A2
(en)
|
2018-07-03 |
2021-05-12 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
JP7534281B2
(ja)
|
2018-07-13 |
2024-08-14 |
ジェンマブ エー／エス |
Ｃｄ３８抗体を使用したトロゴサイトーシスを介した治療
|
|
MA53122A
(fr)
|
2018-07-13 |
2021-05-19 |
Genmab As |
Variants d'anticorps cd38 et leurs utilisations
|
|
MA53812A
(fr)
|
2018-10-04 |
2021-08-11 |
Genmab Holding B V |
Compositions pharmaceutiques comprenant des anticorps anti-cd37 bispécifiques
|
|
US20210369842A1
(en)
|
2018-11-06 |
2021-12-02 |
Genmab A/S |
Antibody formulation
|
|
US20220380440A1
(en)
|
2018-12-31 |
2022-12-01 |
Merus N.V. |
Truncated multivalent multimers
|
|
CN113227132A
(zh)
|
2018-12-31 |
2021-08-06 |
美勒斯公司 |
混合的结合域
|
|
EP3927832A4
(en)
|
2019-02-18 |
2022-11-30 |
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. |
GENETICALLY MODIFIED NON-HUMAN ANIMALS WITH HUMANIZED IMMUNOGLOBULIN LOCUS
|
|
JP7710373B2
(ja)
|
2019-02-21 |
2025-07-18 |
マレンゴ・セラピューティクス，インコーポレーテッド |
Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
|
|
AU2020224681A1
(en)
|
2019-02-21 |
2021-09-16 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to NKp30 and uses thereof
|
|
WO2020172601A1
(en)
|
2019-02-21 |
2020-08-27 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
AU2020226904B2
(en)
|
2019-02-21 |
2025-05-01 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
|
EP3927745A1
(en)
|
2019-02-21 |
2021-12-29 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
|
|
TW202546002A
(zh)
|
2019-03-29 |
2025-12-01 |
荷蘭商美勒斯公司 |
Cd3結合分子
|
|
TWI862565B
(zh)
|
2019-04-04 |
2024-11-21 |
日商小野藥品工業股份有限公司 |
雙特異性抗體
|
|
EP3966241A1
(en)
|
2019-05-09 |
2022-03-16 |
Genmab B.V. |
Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancer
|
|
US20210054049A1
(en)
|
2019-05-09 |
2021-02-25 |
Merus N.V. |
Variant domains for multimerizing proteins and separation thereof
|
|
WO2021006199A1
(ja)
|
2019-07-05 |
2021-01-14 |
小野薬品工業株式会社 |
Ｐｄ－１／ｃｄ３二重特異性タンパク質による血液がん治療
|
|
WO2021020416A1
(ja)
|
2019-07-30 |
2021-02-04 |
小野薬品工業株式会社 |
二重特異性抗体
|
|
EP3772518A1
(en)
|
2019-08-07 |
2021-02-10 |
Merus N.V. |
Modified human variable domains
|
|
GB201912008D0
(en)
|
2019-08-21 |
2019-10-02 |
Cambridge Entpr Ltd |
Antibody
|
|
US20220411529A1
(en)
|
2019-11-06 |
2022-12-29 |
Genmab B.V. |
Antibody variant combinations and uses thereof
|
|
CN114728065A
(zh)
|
2019-11-26 |
2022-07-08 |
上海岸迈生物科技有限公司 |
针对cd3和bcma的抗体和自其制备的双特异性结合蛋白
|
|
CN116199780A
(zh)
|
2019-12-24 |
2023-06-02 |
美勒斯公司 |
TGF-β-RII结合蛋白质
|
|
WO2021138407A2
(en)
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
|
CN116234829A
(zh)
|
2020-01-03 |
2023-06-06 |
马伦戈治疗公司 |
抗tcr抗体分子及其用途
|
|
KR20220130724A
(ko)
|
2020-01-16 |
2022-09-27 |
젠맵 에이/에스 |
Cd38 항체의 제제 및 그의 용도
|
|
CN116407626A
(zh)
|
2020-01-29 |
2023-07-11 |
美勒斯公司 |
用于调节免疫细胞衔接效应的手段和方法
|
|
WO2021155916A1
(en)
|
2020-02-04 |
2021-08-12 |
BioNTech SE |
Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137
|
|
CA3168613A1
(en)
|
2020-03-18 |
2021-09-23 |
Genmab A/S |
Antibodies binding to b7h4
|
|
WO2021211510A2
(en)
*
|
2020-04-13 |
2021-10-21 |
Affyimmune Therapeutics, Inc. |
Epcam antibody and car-t cells
|
|
GB2612450A
(en)
|
2020-04-24 |
2023-05-03 |
Marengo Therapeutics Inc |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
|
CA3176436A1
(en)
|
2020-05-08 |
2021-11-11 |
Tahamtan Ahmadi |
Bispecific antibodies against cd3 and cd20
|
|
MX2022014208A
(es)
|
2020-05-21 |
2022-12-07 |
Merus Nv |
Metodos y medios para la produccion de moleculas tipo ig.
|
|
KR20230018439A
(ko)
|
2020-06-02 |
2023-02-07 |
바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 |
공동 경쇄 면역글로불린 좌위를 갖는 유전자 변형 비인간 동물
|
|
US20230293680A1
(en)
|
2020-07-23 |
2023-09-21 |
Genmab B.V. |
A composition of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma
|
|
WO2022023559A1
(en)
|
2020-07-31 |
2022-02-03 |
Curevac Ag |
Nucleic acid encoded antibody mixtures
|
|
EP4192859A1
(en)
|
2020-08-06 |
2023-06-14 |
BioNTech SE |
Binding agents for coronavirus s protein
|
|
KR20230074487A
(ko)
|
2020-08-26 |
2023-05-30 |
마렝고 테라퓨틱스, 인크. |
Trbc1 또는 trbc2를 검출하는 방법
|
|
AU2021331076A1
(en)
|
2020-08-26 |
2023-04-06 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to NKp30 and uses thereof
|
|
CA3190755A1
(en)
|
2020-08-26 |
2022-03-03 |
Andreas Loew |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
IL301085A
(en)
|
2020-09-10 |
2023-05-01 |
Genmab As |
A bispecific antibody against CD3 and CD20 in combination therapy for the treatment of diffuse large B-cell lymphoma
|
|
AU2021342342A1
(en)
|
2020-09-10 |
2023-04-13 |
Genmab A/S |
Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leukemia
|
|
BR112023005742A2
(pt)
|
2020-10-02 |
2023-05-02 |
Genmab As |
Anticorpo, composição, composição farmacêutica, método para tratar uma doença, ácido nucléico, vetor de expressão, célula, método para produzir um anticorpo, kit de partes, e, anticorpo anti-idiotípico
|
|
JP2023554422A
(ja)
|
2020-12-16 |
2023-12-27 |
メルス ナムローゼ フェンノートシャップ |
がんの治療のための多重特異性抗体
|
|
US20240150484A1
(en)
|
2021-03-12 |
2024-05-09 |
Genmab A/S |
Non-activating antibody variants
|
|
CA3214757A1
(en)
|
2021-04-08 |
2022-10-13 |
Andreas Loew |
Multifuntional molecules binding to tcr and uses thereof
|
|
IL308300A
(en)
|
2021-05-07 |
2024-01-01 |
Genmab As |
PHARMACEUTICAL COMPOSITIONS COMPRISING BISPECIFIC ANTIBODIES BINDING TO B7H4 and CD3
|
|
JP2024523438A
(ja)
|
2021-06-21 |
2024-06-28 |
ジェンマブ エー／エス |
Ｃｄ１３７結合物質とｐｄ－ｌ１結合物質の組合せ投薬レジメン
|
|
KR20240051280A
(ko)
|
2021-09-06 |
2024-04-19 |
젠맵 에이/에스 |
Cd27과 결합할 수 있는 항체, 그의 변이체 및 그의 용도
|
|
AR127298A1
(es)
|
2021-10-08 |
2024-01-10 |
Genmab As |
Anticuerpos que se unen a cd30 y cd3
|
|
EP4469476A1
(en)
|
2022-01-25 |
2024-12-04 |
Merus N.V. |
Combination therapy for the treatment of cancer
|
|
WO2023174521A1
(en)
|
2022-03-15 |
2023-09-21 |
Genmab A/S |
Binding agents binding to epcam and cd137
|
|
TW202413412A
(zh)
|
2022-05-12 |
2024-04-01 |
丹麥商珍美寶股份有限公司 |
在組合療法中能夠結合到ｃｄ２７之結合劑
|
|
WO2023218051A1
(en)
|
2022-05-12 |
2023-11-16 |
Genmab A/S |
Binding agents capable of binding to cd27 in combination therapy
|
|
JP2025524728A
(ja)
|
2022-07-15 |
2025-07-30 |
フィアン セラピューティクス エルティーディー |
抗体－薬物複合体
|
|
US20250382378A1
(en)
|
2022-10-31 |
2025-12-18 |
Genmab A/S |
Cd38 antibodies and uses thereof
|
|
WO2024143442A1
(ja)
|
2022-12-27 |
2024-07-04 |
中外製薬株式会社 |
会合が制御されたポリペプチド
|
|
CN116333103B
(zh)
*
|
2023-02-09 |
2025-10-10 |
广州国家实验室 |
抗沙贝病毒属病毒的中和抗体及其制备方法和应用
|
|
WO2024208898A1
(en)
|
2023-04-05 |
2024-10-10 |
Genmab A/S |
Pharmaceutical compositions comprising antibodies binding to cd30 and cd3
|
|
CN121285385A
(zh)
|
2023-05-12 |
2026-01-06 |
金麦安博股份有限公司 |
能够与ox40结合的抗体、其变体及其用途
|
|
AR133071A1
(es)
|
2023-06-30 |
2025-08-20 |
Genmab As |
ANTICUERPOS QUE SE UNEN A LA PROTEÍNA DE ACTIVACIÓN DE FIBROBLASTOS a Y AL RECEPTOR DE MUERTE 4
|
|
WO2025056180A1
(en)
|
2023-09-15 |
2025-03-20 |
BioNTech SE |
Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
|
|
TW202540189A
(zh)
|
2023-11-30 |
2025-10-16 |
德商生物新技術公司 |
在組合療法中能夠結合ｏｘ４０之抗體
|
|
WO2025149667A1
(en)
|
2024-01-12 |
2025-07-17 |
Pheon Therapeutics Ltd |
Antibody drug conjugates and uses thereof
|
|
WO2025262641A1
(en)
|
2024-06-19 |
2025-12-26 |
Pheon Therapeutics Ltd |
Antibody drug conjugates that bind cdcp1 and uses thereof
|
|
WO2026011013A1
(en)
|
2024-07-02 |
2026-01-08 |
Epibiologics, Inc. |
Binding agents and uses thereof
|
|
WO2026050572A2
(en)
|
2024-08-29 |
2026-03-05 |
Marengo Therapeutics, Inc. |
Multifunctional molecules binding to tcr and uses thereof
|
|
WO2026078443A1
(en)
|
2024-10-11 |
2026-04-16 |
Pheon Therapeutics Ltd. |
Antibody drug conjugates that bind cdcp1 and uses thereof
|